Market research
4NX1.F Lumos Pharma, Inc
F EUR Not available
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 64M
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- Not available
- Beta
- Not available
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 64M
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- Not available
- Beta
- Not available
About
About Lumos Pharma, Inc
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
Research context
Lumos Pharma, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4NX1.F discussion.
5 years, 7 months ago
Lumos Pharma, Inc is currently in a long term downtrend where the price is trading 32.7% below its 200 day moving average.
From a valuation standpoint, the stock is 64.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 466.0.
Lumos Pharma, Inc's total revenue sank by 90.8% to $40K since the same quarter in the previous year.
Its net income has increased by 70.8% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.9% to $-7M since the same quarter in the previous year.
Based on the above factors, Lumos Pharma, Inc gets an overall score of 3/5.